Makale
Tam Makale
Uluslararası
2019
Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations
Current Pharmaceutical Analysis
Cilt 15 · Sayı 5 · ss. 554–559 · 01.01.2019
Özet
Introduction: Macitentan is an endothelin receptor antagonist drug used in the treatment of pulmonary arterial hypertension.
Anahtar kelimeler
VALIDATION
UPLC-MS/MS
Pharmacokinetics
macitentan
pulmonary arterial hypertension
ENDOTHELIN-RECEPTOR ANTAGONIST
pharmaceutical formulations
specificity
Atıf için künye
Albayrak, M., & Atila, A. (2019). Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations. Current Pharmaceutical Analysis, 15(5), 554–559. https://doi.org/10.2174/1573412915666190314142531
BibTeX
@article{albayrak2019-22995,
author = {Albayrak, Mevlüt and Atila, Alptuğ},
title = {Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations},
journal = {Current Pharmaceutical Analysis},
year = {2019},
volume = {15},
number = {5},
pages = {554--559},
issn = {1573-4129},
doi = {10.2174/1573412915666190314142531},
url = {https://akademik.atauni.edu.tr/yayinlar/22995-development-and-validation-of-novel-uplc-msms-method-for-the-analysis-of}
}